

SELUTION SLR™ DEB

# DRUG ELUTION DONE BETTER

## SUMMARY OF SELUTION SFA JAPAN 3 YEAR TRIAL



The next step in the evolution of *Leave Nothing Behind* with **Sustained Limus Release**.

Consistent performance in complex patients show **SELUTION SLR™ Drug-Eluting Balloon** meets or exceeds effectiveness of paclitaxel eluting technologies.

## TRIAL DESIGN

A prospective, multi-center, single arm trial evaluation of real world superficial femoral artery PAD population in Japan at 3 years. Primary end-point was primary patency of the target lesion at 12 months.<sup>1</sup>

**134** | **13**  
PATIENTS | SITES

JAPAN



Scan the  
QR Code to  
learn more

**12.7cm**  
LESION LENGTH


**11.2%**  
SEVERE  
CALCIFICATION

**20.9%**  
CTO


**60.3%**  
DIABETES

# THE ONLY DRUG-ELUTING TECHNOLOGY WITH PROVEN 3-YEAR PATENCY OVER 80%


PRIMARY PATENCY AT 3 YEARS




FREEDOM FROM CD-TLR AT 3 YEARS



POSITIVE RESULTS THAT ARE COMPARABLE TO PACLITAXEL DCBS\*



RESTENOSIS RATE COMPARISON VS. PACLITAXEL DCBS\*



\*Data is based on a cross-trial comparison and not head-to-head clinical trials, the data may not be directly comparable due to differences in study protocols, conditions and patient populations. All values rounded to the nearest unit.

## SELUTION SLR<sup>™</sup> DEB RESULTS WITHOUT COMPROMISE

**0.0%** AMPUTATION

**0.0%** DEVICE RELATED DEATHS

1. 36 Months Japan SFA Trial, Oral Presentation, JET 2025.  
 2. Sachar R, et al. Cardiovascular Interventions 14.10 (2021): 1123-1133. and Brodmann M, Oral Presentation LINC 2023  
 3. Soga Y, Iida O. et al. Journal of Endovascular Therapy 27.6 (2020): 946-955.

**For Healthcare Professionals Only.**

Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification. Please contact your Cordis representative for additional product availability information. SELUTION SLR Drug-Eluting Balloon, CE 0344, is manufactured by M.A. Med Alliance SA and its affiliates. SELUTION SLR is a trademark of M.A. Med Alliance SA. M.A. Med Alliance SA is a Cordis company. CORDIS and Cordis LOGO are Trademarks of Cordis and may be registered in the US and/or in other countries. All other marks are the property of their respective owners.

